Key result
Spironolactone and dapagliflozin improve diastolic dysfunction and prevent hospitalizations in a HFpEF case.
Why the study?
The study was conducted to observe the benefit of a mineralocorticoid receptor antagonist and SGLT2 inhibitor in HFpEF in rural Tanzania, an African population underrepresented in trials.
Does the combination of dapagliflozin and spironolactone improve clinical symptoms and prevent hospitalizations in a rural African patient with HFpEF?
Case Report (n=1)
No
Does the combination of dapagliflozin and spironolactone improve clinical symptoms and prevent hospitalizations in a rural African patient with HFpEF?
Answers are grounded in this paper and cite their sources.
The addition of dapagliflozin and spironolactone to standard therapy successfully improved symptoms, echocardiographic parameters, and prevented recurrent hospitalizations in a rural African patient with HFpEF.
Objective: To observe the benefit of mineralocorticoid receptor antagonist and sodium-glucose co-transport 2 inhibitor (SGLT2 inhibitor) in heart failure preserved ejection (HFpEF) in rural Tanzania. Background and Result: The use of spironolactone and dapagliflozin was shown to be effective in improving the clinical outcome and reducing CV hospitalization rate and CV mortality in patients with heart failure preserved left ventricular ejection fraction (HFpEF). This is the case presentation of one patient with HFpEF with diastolic dysfunction grade 3, obesity grade 3, Type 2 Diabetes, and Atrial Fibrillation (permanent). In the case of a 76-year-old female after previous ineffective treatment, the initiation of Spironolactone and Dapagliflozin led to a rapid and marked improvement in the clinical conditions. Diastolic dysfunction was improved from stage III to stage I. Moreover, the initiation of spironolactone and dapagliflozin therapy avoided a referral for surgical intervention and interrupted a long series of hospitalizations for acute HF and prevented CV death. Conclusion: Based on our experience, we conclude that the treatment with spironolactone and dapagliflozin allows for better treatment optimization with a positive impact on the control of clinical outcomes and preventing CV death and CV hospitalization in HFpEF and related comorbidities in the African population, which is underrepresented in most of the trials.
No takes yet. Share an insight, caveat, or question.
Raphael et al. (2022) conducted a case report in Heart Failure with Preserved Ejection Fraction (HFpEF) (n=1). Dapagliflozin and Spironolactone vs. Previous therapy was evaluated on Clinical symptoms and diastolic dysfunction. The initiation of spironolactone and dapagliflozin in a 76-year-old female with HFpEF improved diastolic dysfunction from stage III to stage I and prevented further hospitalizations.
Synapse has enriched 10 related papers. Consider them for comparative context: